Alzheimer’s disease, frontotemporal dementias, progressive supranuclear palsy, Corticobasal degeneration, Clinical Trial Study
< Back to Find a Trial

Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease (I5T-MC-AACI)

ID
NCT04437511
Condition Studied
Alzheimer's Disease
Phase
Phase III
Status
Active, but no longer recruiting
Intervention
Donanemab
Principal Investigator
Sponsor
Eli Lilly and Company
Contact Coordinator

Please go to ClinicalTrials.gov for more information.